Work

P2.06.100 Initial Biomarker Results From the Phase 2A Study of AFM24 With Atezolizumab in Patients With Advanced/Metastatic NSCLC

Year: 2025

Type: article

Study design: Clinical Trial

Source: Journal of Thoracic Oncology

DOI: 10.1016/j.jtho.2025.09.634

Authors: H.R. Kim, A. Oberoi, J.S. Lopez, A.B. El-Khoueiry, O. Saavedra, A. Cervantes, V. Boni, J.S. Thomas, W. Rogowski, I. Lugowska, E. Christenson, B.Y. Shim, J.W. Kim, R. Ramlau, U. Gärtner, D. Schütz, S. Staeble, K. Pietzko, M. Emig, D. Morales-Espinosa

Institutions: Yonsei University, Yonsei University Health System, Yonsei Cancer Hospital, Vall d'Hebron Institute of Oncology, Institute of Cancer Research, University of Southern California, USC Norris Comprehensive Cancer Center, Hospital Clínico Universitario de Valencia, Hospital Universitario Quirónsalud Madrid, The Maria Sklodowska-Curie National Research Institute of Oncology, Johns Hopkins University, Johns Hopkins Hospital, The Catholic University of Korea St. Vincent's Hospital, Seoul National University, Poznan University of Medical Sciences

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4415520113

FWCI:

Cites:

Cited by:

Related to: